325 related articles for article (PubMed ID: 31642908)
1. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
Zen M; Fuzzi E; Loredo Martinez M; Depascale R; Fredi M; Gatto M; Larosa M; Saccon F; Iaccarino L; Doria A
Rheumatology (Oxford); 2022 Feb; 61(2):688-695. PubMed ID: 33909900
[TBL] [Abstract][Full Text] [Related]
3. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study.
Fasano S; Coscia MA; Pierro L; Ciccia F
Lupus; 2021 May; 30(6):991-997. PubMed ID: 33709836
[TBL] [Abstract][Full Text] [Related]
4. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.
Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Mitjavila F; Castro Salomó A; Cuquet Pedragosa J; Ortiz-Santamaria V; Mauri Plana M; Cortés-Hernández J
Ann Rheum Dis; 2017 Sep; 76(9):1575-1582. PubMed ID: 28450313
[TBL] [Abstract][Full Text] [Related]
5. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort.
Ugarte-Gil MF; Wojdyla D; Pastor-Asurza CA; Gamboa-Cárdenas RV; Acevedo-Vásquez EM; Catoggio LJ; García MA; Bonfá E; Sato EI; Massardo L; Pascual-Ramos V; Barile LA; Reyes-Llerena G; Iglesias-Gamarra A; Molina-Restrepo JF; Chacón-Díaz R; Alarcón GS; Pons-Estel BA
Lupus; 2018 Apr; 27(4):536-544. PubMed ID: 28857715
[TBL] [Abstract][Full Text] [Related]
7. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
[TBL] [Abstract][Full Text] [Related]
8. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
[TBL] [Abstract][Full Text] [Related]
11. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
[TBL] [Abstract][Full Text] [Related]
12. Disease Flare of Systemic Lupus Erythematosus in Patients With Endstage Renal Disease on Dialysis.
Kim YE; Choi SJ; Lim DH; Kim H; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
J Rheumatol; 2022 Oct; 49(10):1131-1137. PubMed ID: 35970534
[TBL] [Abstract][Full Text] [Related]
13. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
van Vollenhoven R; Voskuyl A; Bertsias G; Aranow C; Aringer M; Arnaud L; Askanase A; Balážová P; Bonfa E; Bootsma H; Boumpas D; Bruce I; Cervera R; Clarke A; Coney C; Costedoat-Chalumeau N; Czirják L; Derksen R; Doria A; Dörner T; Fischer-Betz R; Fritsch-Stork R; Gordon C; Graninger W; Györi N; Houssiau F; Isenberg D; Jacobsen S; Jayne D; Kuhn A; Le Guern V; Lerstrøm K; Levy R; Machado-Ribeiro F; Mariette X; Missaykeh J; Morand E; Mosca M; Inanc M; Navarra S; Neumann I; Olesinska M; Petri M; Rahman A; Rekvig OP; Rovensky J; Shoenfeld Y; Smolen J; Tincani A; Urowitz M; van Leeuw B; Vasconcelos C; Voss A; Werth VP; Zakharova H; Zoma A; Schneider M; Ward M
Ann Rheum Dis; 2017 Mar; 76(3):554-561. PubMed ID: 27884822
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
Mok CC; Ho LY; Tse SM; Chan KL
Ann Rheum Dis; 2017 Aug; 76(8):1420-1425. PubMed ID: 28432050
[TBL] [Abstract][Full Text] [Related]
15. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.
Ji L; Gao D; Hao Y; Huang H; Wang Y; Deng X; Geng Y; Zhang Z
Rheumatology (Oxford); 2022 Dec; 62(1):181-189. PubMed ID: 35412598
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis.
Ji L; Xie W; Fasano S; Zhang Z
Lupus Sci Med; 2022 Jan; 9(1):. PubMed ID: 34996857
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus.
Chang JC; Costenbader KH
Semin Arthritis Rheum; 2022 Oct; 56():152042. PubMed ID: 35738041
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
20. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
